5 Investors to Follow Other Than Warren Buffett
There is no doubt that Warren Buffett is one of…
Sell
26
NTLA Quote, Financials, Valuation and Earnings
Last price:
$8.29
Seasonality move
:
32.19%
Day range:
$7.24 - $8.54
52-week range:
$5.90 - $28.18
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
12.45x
P/B ratio:
0.87x
Volume:
3.7M
Avg. volume:
3.6M
1-year change:
-69.47%
Market cap:
$754.6M
Revenue:
$57.9M
EPS (TTM):
-$5.25
Analysts' Opinion
-
Consensus RatingIntellia Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 18 Buy ratings, 6 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $41.81, Intellia Therapeutics has an estimated upside of 473.59% from its current price of $7.29.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $8.00 representing -9.74% downside risk from its current price of $7.29.
Fair Value
-
According to the consensus of 24 analysts, Intellia Therapeutics has 473.59% upside to fair value with a price target of $41.81 per share.
NTLA vs. S&P 500
-
Over the past 5 trading days, Intellia Therapeutics has underperformed the S&P 500 by -17.01% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Intellia Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Intellia Therapeutics revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Intellia Therapeutics reported revenues of $12.9M.
Earnings Growth
-
Intellia Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Intellia Therapeutics reported earnings per share of -$1.27.
Enterprise value:
153.1M
EV / Invested capital:
--
Price / LTM sales:
12.45x
EV / EBIT:
--
EV / Revenue:
2.65x
PEG ratio (5yr expected):
-1.19x
EV / Free cash flow:
-0.43x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
-42.43%
Net Income Margin (TTM):
-896.77%
Return On Equity:
-53.05%
Return On Invested Capital:
-53.05%
Operating Margin:
-1059.87%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $52.1M | $36.3M | $57.9M | -$1.9M | $12.9M | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$458.2M | -$515.3M | -$534.3M | -$139.9M | -$136.4M | |
| EBITDA | -$450.6M | -$506.3M | -$524M | -$137.4M | -$133.9M | |
| Diluted EPS | -$6.18 | -$5.41 | -$5.25 | -$1.46 | -$1.27 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $616.5M | $769.3M | $1.2B | $998.3M | $639.9M | |
| Total Assets | $676.3M | $1.3B | $1.5B | $1.3B | $1.2B | |
| Current Liabilities | $64.3M | $125.8M | $126.6M | $115.2M | $110.9M | |
| Total Liabilities | $149.3M | $254.2M | $284.5M | $250.8M | $319.1M | |
| Total Equity | $527.1M | $1B | $1.2B | $1.1B | $872M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$333.3M | -$394.1M | -$348.9M | -$93.1M | -$85.2M | |
| Cash From Investing | $160.3M | -$31.3M | $125.6M | $45.9M | $151.6M | |
| Cash From Financing | $583M | $130.3M | $185.7M | $106.5M | $2.3M | |
| Free Cash Flow | -$391.7M | -$408.1M | -$354.7M | -$94.6M | -$86.2M | |
NTLA
Sector
Market Cap
$754.6M
$34.5M
Price % of 52-Week High
25.87%
43.57%
Dividend Yield
0%
0%
Shareholder Yield
-14.87%
-0.79%
1-Year Price Total Return
-69.47%
-42.08%
Beta (5-Year)
2.332
0.660
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$8.25
200-day SMA
Sell
Level
$14.87
Bollinger Bands (100)
Sell
Level
0 - 0
Chaikin Money Flow
Sell
Level
--
20-day SMA
Buy
Level
$7.85
Relative Strength Index (RSI14)
Buy
Level
51.86
ADX Line
Neutral
Level
0
Williams %R
Buy
Level
-80.1531
50-day SMA
Sell
Level
$8.42
MACD (12, 26)
Sell
Level
-0.05
25-day Aroon Oscillator
Buy
Level
72
On Balance Volume
Neutral
Level
--
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.221)
Sell
CA Score
(Annual)
Level (-1.1349)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (2.4399)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
Stock Forecast FAQ
In the current month, NTLA has received 18 Buy ratings 6 Hold ratings, and 0 Sell ratings. The NTLA average analyst price target in the past 3 months is $41.81.
-
Where Will Intellia Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Intellia Therapeutics share price will rise to $41.81 per share over the next 12 months.
-
What Do Analysts Say About Intellia Therapeutics?
Analysts are divided on their view about Intellia Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Intellia Therapeutics is a Sell and believe this share price will drop from its current level to $8.00.
-
What Is Intellia Therapeutics's Price Target?
The price target for Intellia Therapeutics over the next 1-year time period is forecast to be $41.81 according to 24 Wall Street analysts, 18 of them rate the stock a Buy, 0 rate the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is NTLA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Intellia Therapeutics is a Buy. 18 of 24 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NTLA?
You can purchase shares of Intellia Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Intellia Therapeutics shares.
-
What Is The Intellia Therapeutics Share Price Today?
Intellia Therapeutics was last trading at $8.29 per share. This represents the most recent stock quote for Intellia Therapeutics. Yesterday, Intellia Therapeutics closed at $7.29 per share.
-
How To Buy Intellia Therapeutics Stock Online?
In order to purchase Intellia Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is BYD a Threat To Tesla Shareholders?
BYD (OTC:BYDDY) has rocketed to the top of China’s booming…
CVX Vs XOM Stock, Which Energy Play Is Best?
Chevron (NYSE:CVX) and Exxon Mobil (NYSE:XOM) are two of the…
Stock Ideas
Buy
70
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 32x
Buy
61
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Buy
60
RGC alert for May 8
Regencell Bioscience Holdings [RGC] is up 10.54% over the past day.
Buy
92
TPB alert for May 8
Turning Point Brands [TPB] is down 6.67% over the past day.
Buy
74
LIVN alert for May 8
LivaNova PLC [LIVN] is up 1.33% over the past day.
